Linker Information
General Information of This Linker
| Linker ID |
LIN0AEDTK
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
Succynimidyloxycarbonyl-alpha-methyl-alpha-(2-pyridyl-dithio) toluene (SMPT)
|
|||||
| Linker Type |
Rigid dual-reactive (amino/thiol) linker; Thiol-sensitive linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C18H16N2O4S2
|
|||||
| Isosmiles |
CC(C1=CC=C(C=C1)C(=O)ON2C(=O)CCC2=O)SSC3=CC=CC=N3
|
|||||
| PubChem CID | ||||||
| InChI |
InChI=1S/C18H16N2O4S2/c1-12(25-26-15-4-2-3-11-19-15)13-5-7-14(8-6-13)18(23)24-20-16(21)9-10-17(20)22/h2-8,11-12H,9-10H2,1H3
|
|||||
| InChIKey |
GKSPIZSKQWTXQG-UHFFFAOYSA-N
|
|||||
| IUPAC Name |
(2,5-dioxopyrrolidin-1-yl) 4-[1-(pyridin-2-yldisulfanyl)ethyl]benzoate
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
388.5
|
Polar area
|
127
|
||
|
Complexity
|
521
|
xlogp Value
|
2.6
|
|||
|
Heavy Count
|
26
|
Rot Bonds
|
7
|
|||
|
Hbond acc
|
7
|
Hbond Donor
|
0
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
RFB4-SMPT-dgA [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients must have CD22+ (≥30%) B-cell NHL (excluding CLL, ALL, and hairy cell leukemia), measurable disease (excluding marrow-only involvement), and progression post-chemotherapy, with adequate organ function (CrCl >60 mL/min, bilirubin <1.5 mg/dL, EF ≥35% if prior doxorubicin).Key exclusions include HIV, CNS/pulmonary involvement, recent chemotherapy (<2 weeks), and transplant candidates. Required labs: SGPT <2x ULN, albumin >75% LLN, PS 0-2, and life expectancy ≥3 months.
Click to Show/Hide
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00001271 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma
|
||||
References